OR WAIT null SECS
February 07, 2023
Clinicians, pediatric patients, regulators, and more are being considered to further strengthen focus on unmet medical needs.
Thermo Fisher and Celltrio are introducing a new automation platform to address critical scale-up challenges in biotherapeutics.
Naoki Okamura, Astellas’ current chief strategy officer, will take over the role from Kenji Yasukawa.
CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.
iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.
February 06, 2023
The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing.